<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="141199">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01857583</url>
  </required_header>
  <id_info>
    <org_study_id>DU176b-B-J306</org_study_id>
    <nct_id>NCT01857583</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetics Study of DU-176b Administered to Patients With Severe Renal Impairment Undergoing Orthopedic Surgery of The Lower Limbs</brief_title>
  <official_title>Phase III Clinical Study of DU-176b (Venous Thromboembolism): Japanese, Multicenter, Open-label Study of DU-176b in Patients With Severe Renal Impairment (SRI) Undergoing Orthopedic Surgery of the Lower Limbs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo Inc.</source>
  <oversight_info>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the safety and pharmacokinetics of DU-176b administered to patients with severe
      renal impairment undergoing orthopedic surgery of the lower limbs, compared with DU-176b
      administered to patients with mild renal impairment (MiRI) undergoing orthopedic surgery of
      the lower limbs.

      For reference, the safety of DU-176b in patients with SRI undergoing orthopedic surgery of
      the lower limbs will be compared with that of fondaparinux.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Incidence of any bleeding events</measure>
    <time_frame>14 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Incidence of any bleeding events (including major bleeding, clinically relevant non-major bleeding, and minor bleeding).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>1 month</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse drug reactions</measure>
    <time_frame>1 month</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of DU-176b</measure>
    <time_frame>14 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of D21-2393</measure>
    <time_frame>14 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adjudicated thromboembolic events</measure>
    <time_frame>1 month</time_frame>
    <safety_issue>No</safety_issue>
    <description>Incidence of adjudicated thromboembolic events (symptomatic Deep Vein Thrombosis [DVT], symptomatic Pulmonary Thromboembolism [PTE], Venous Thromboembolism [VTE] related deaths).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Venous Thromboembolism</condition>
  <arm_group>
    <arm_group_label>SRI 15mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Severe Renal Impairment group orally administered 15mg DU-176b once daily for 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MiRI 30mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mild Renal Impairment group orally administered 30mg DU176b once daily for 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fondaparinux</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fondaparinux subcutaneously administered at a dose of 1.5mg once daily for 14 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>15mg DU-176b</intervention_name>
    <arm_group_label>SRI 15mg</arm_group_label>
    <other_name>edoxaban</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>30mg DU-176b</intervention_name>
    <arm_group_label>MiRI 30mg</arm_group_label>
    <other_name>edoxaban</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fondaparinux</intervention_name>
    <arm_group_label>Fondaparinux</arm_group_label>
    <other_name>Arixtra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with SRI or MiRI undergoing orthopedic surgery of the lower limbs

        Exclusion Criteria:

          -  Patients who are on hemodialysis or are scheduled to undergo hemodialysis during the
             study period

          -  Patients who are at a significantly high risk for bleeding or thromboembolism

          -  Patients who are receiving another antithrombotic therapy and are unable to suspend
             the therapy

          -  Patients who have evidence of hepatic function test abnormalities
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Takeshi Fuji, VP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Osaka Koseinenkin Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Toyooka Chuo Hospital</name>
      <address>
        <city>Asahikawa</city>
        <state>Hokkaido Prefecture</state>
        <zip>078-8237</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 16, 2013</lastchanged_date>
  <firstreceived_date>May 16, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>anticoagulant</keyword>
  <keyword>DU-176b</keyword>
  <keyword>edoxaban</keyword>
  <keyword>factor Xa</keyword>
  <keyword>oral</keyword>
  <keyword>orthopedic surgery of lower limbs</keyword>
  <keyword>severe renal impairment</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fondaparinux</mesh_term>
    <mesh_term>PENTA</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
